These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22022380)

  • 1. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations.
    Hubner RA; Riley RD; Billingham LJ; Popat S
    PLoS One; 2011; 6(10):e25164. PubMed ID: 22022380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Yang Y; Xian L
    Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    Mol Biol Rep; 2012 Jun; 39(6):6933-42. PubMed ID: 22302397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.
    Yu D; Shi J; Sun T; Du X; Liu L; Zhang X; Lu C; Tang X; Li M; Xiao L; Zhang Z; Yuan Q; Yang M
    Tumour Biol; 2012 Jun; 33(3):877-84. PubMed ID: 22249976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
    J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer.
    Huang SJ; Wang YF; Jin ZY; Sun JY; Guo ZL
    Tumour Biol; 2014 May; 35(5):4023-9. PubMed ID: 24370899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.
    Yang Y; Luo X; Yang N; Feng R; Xian L
    PLoS One; 2014; 9(11):e111651. PubMed ID: 25375151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis.
    Yao A; Wang Y; Peng X; Ye R; Wang Q; Qi Y; Zhou F
    J Cancer Res Clin Oncol; 2014 Dec; 140(12):2107-17. PubMed ID: 24994039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
    Ganzinelli M; Linardou H; Alvisi MF; Caiola E; Lo Russo G; Cecere FL; Bettini AC; Psyrri A; Milella M; Rulli E; Fabbri A; De Maglie M; Romanelli P; Murray S; Broggini M; Marabese M; Garassino MC
    ESMO Open; 2021 Feb; 6(1):100034. PubMed ID: 33422766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Roth JA; Carlson JJ
    Clin Lung Cancer; 2011 Nov; 12(6):393-401. PubMed ID: 21723790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.
    Wei HB; Lu XS; Shang LH; Xu G; Hu J; Che DH; Liu F; Wu Y; Zhang GM; Yu Y
    Arch Med Res; 2011 Jul; 42(5):412-20. PubMed ID: 21827803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer.
    Breen D; Barlési F
    Eur J Cardiothorac Surg; 2008 May; 33(5):805-11. PubMed ID: 18342529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodological quality evaluation of systematic reviews or meta-analyses on ERCC1 in non-small cell lung cancer: a systematic review.
    Tao H; Zhang Y; Li Q; Chen J
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2245-2256. PubMed ID: 28875225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.
    Wei HB; Hu J; Shang LH; Zhang YY; Lu FF; Wei M; Yu Y
    Chin Med J (Engl); 2012 Aug; 125(16):2902-7. PubMed ID: 22932088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.
    Yin M; Yan J; Voutsina A; Tibaldi C; Christiani DC; Heist RS; Rosell R; Booton R; Wei Q
    Lung Cancer; 2011 Jun; 72(3):370-7. PubMed ID: 21075476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
    Zhang H; Li J; Zhang Y; Sun M; Zhao P; Zhang G; Jin C; Sun L; He M; Wang B; Zhang X
    Genet Mol Res; 2014 Dec; 13(4):10215-22. PubMed ID: 25501233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.